

Online supplement

Table A1. Duration of follow-up from first rituximab infusion to last control visit by diagnosis

Diagnosis	Patients, n (%)	Median (range) follow-up, months
<i>Total</i>	370	6.5 (0–56.6)
Arthritis (non-RA)/ ankylosing spondylitis/ psoriatic arthritis	6 (1.6)	4.4 (0–9.0)
Autoimmune haemolytic anaemia	3 (0.8)	8.5 (3.7–30.9)
Autoimmune thrombocytopenia	10 (2.7)	6.2 (2.0–32.0)
Glomerulonephritis	9 (2.4)	8.5 (0–24.5)
Cryoglobulinaemic vasculitis	5 (1.4)	8.3 (0–23.7)
Wegener’s granulomatosis/ microscopic polyangiitis	58 (15.7)	16.8 (0–56.6)
Multiple sclerosis/ neuromyelitis optica	56 (15.1)	7.1 (0–29.7)
Myasthenia gravis	5 (1.4)	5.6 (0–35.1)
Pemphigus	37 (10.0)	11.6 (1.1–36.9)
Sjögren’s syndrome	6 (1.6)	6.2 (0–25.1)
Polydermatomyositis	26 (7.0)	8.5 (0–33.7)
Systemic lupus erythematosus	85 (23.0)	7.5 (0–49.8)
Vasculitis	13 (3.5)	3.7 (0–19.2)
Overlap syndromes: mixed connective tissue disease	19 (5.1)	0
Others ^a	32 (8.6)	0

Table A2. Number of rituximab infusions by diagnosis

Diagnosis	Number of rituximab infusions																			
	1		2		3		4		5		6		7		8		>8			
	N	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	
Overall	370	50	13.5	145	39.2	15	4.1	126	34.1	9	2.4	5	1.4	3	0.8	14	3.9	3	0.8	
Arthritis (non-RA)/ankylosing spondylitis/psoriatic arthritis	6	.	.	5	83.3	.	.	1	16.7	
Autoimmune haemolytic anaemia	3	.	.	1	33.3	.	.	2	66.7	
Autoimmune thrombocytopenia	10	1	10.0	1	10.0	.	.	7	70.0	1	10.0	
Glomerulonephritis	9	1	11.1	4	44.4	1	11.1	2	22.2	1	11.1	.	.	
Cryoglobulinaemic vasculitis	5	.	.	2	40.0	.	.	2	40.0	1	20.0	
Wegener's granulomatosis/microscopic polyangiitis	58	3	5.2	17	29.3	3	5.2	23	39.7	2	3.4	.	.	1	1.7	8	13.8	1	1.7	
Multiple sclerosis/neuromyelitis optica	56	3	5.4	15	26.8	4	7.1	31	55.4	1	1.8	1	1.8	1	1.8	
Myasthenia gravis	5	1	20.0	2	40.0	1	20.0	1	20.0	
Pemphigus	37	16	43.2	11	29.7	.	.	8	21.6	1	2.7	1	2.7	.	.	
Sjögren's syndrome	6	1	16.7	3	50.0	.	.	2	33.3	
Polydermatomyositis	26	3	11.5	14	53.8	.	.	5	19.2	1	3.8	1	3.8	.	.	1	3.8	1	3.8	
Systemic lupus erythematosus	85	10	11.8	41	48.2	4	4.7	24	28.2	1	1.2	3	3.5	.	.	2	2.4	.	.	
Vasculitis	13	2	15.4	7	53.8	.	.	4	30.8	
Overlap syndromes: mixed connective tissue disease	19	.	.	12	63.2	1	5.3	3	15.8	3	15.8	
Other	32	9	28.1	10	31.3	1	3.1	11	34.4	.	.	1	3.1	